Drugs / HSK31858
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07134465 | Aug 2025 → Nov 2026 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07134478 | Oct → Dec 2024 overdue | — | Haisco Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06569784 | May → Jul 2024 overdue | — | Xizang Haisco Pharmaceutical Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05663593 | Feb → Aug 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05023525 | Oct 2021 → Apr 2022 | — | Haisco Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT06820749 | Dec 2024 → Apr 2026 overdue | asthma, bronchiectasis | Haisco Pharmaceutical Group Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06637254 | Oct 2024 → Mar 2026 overdue | asthma | Haisco Pharmaceutical Group Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05601778 | Dec 2022 → Mar 2024 | bronchiectasis | Haisco Pharmaceutical Group Co., Ltd. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07616375 | Sep 2025 → Jan 2029 expected | bronchiectasis | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06660992 | Sep 2024 → Nov 2026 expected | bronchiectasis | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK31858 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06637254 ↗ |
| Known as | [14C]HSK31858 | “A single oral dose of 40 mg/120 μCi \[14C\]HSK31858 after fasting for at least 10 hours.” NCT06569784 ↗ |
| Action | Inhibit | “HSK31858 is a novel reversible inhibitor of DPP-1.” PMID 40154523 ↗ Mar 2025 |
| Route | Oral | “orally” PMID 40154523 ↗ Mar 2025 |
| Target | DPP1 | “novel inhibitor of DPP1” NCT05601778 ↗ |